The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis
Open Access
- 22 July 2016
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1-19
Abstract
Rosacea is a common chronic skin condition that manifests as recurrent inflammatory lesions. Long-term treatment is required to control symptoms and disease progression, with topical treatments being the first-line choice. Ivermectin 1 % cream is a new once-daily (QD) topical treatment for the inflammatory lesions of rosacea, and it is important to compare the efficacy, safety, and tolerability of ivermectin with other currently available topical treatments. A systematic literature review was performed from January 2011 to June 2015, with articles published prior to 2011 retrieved from a Cochrane review on rosacea. Randomized controlled trials of the topical treatment of adult patients with moderate-to-severe papulopustular rosacea were identified from electronic databases and trial registers, and supplemented with data from clinical study reports. Mixed treatment comparisons (MTCs) were conducted to compare different treatments according to Bayesian methodology. 57 studies were identified, with 19 providing data suitable for MTC. Ivermectin 1 % cream QD led to a significantly greater likelihood of success compared with azelaic acid 15 % gel twice-daily (BID) [relative risk (95 % credible interval): 1.25 (1.14–1.37)], and metronidazole 0.75 % cream BID [1.17 (1.08–1.29)] at 12 weeks. Ivermectin 1 % cream QD also demonstrated a significant reduction in inflammatory lesion count compared with azelaic acid 15 % gel BID [−8.04 (−12.69 to −3.43)] and metronidazole 0.75 % cream BID [−9.92 (−13.58 to −6.35)] at 12 weeks. Ivermectin 1 % cream QD led to a significantly lower risk of developing any AE or TRAE compared with azelaic acid 15 % gel BID [0.83 (0.71–0.97) and 0.47 (0.32–0.67), respectively]. Ivermectin 1 % cream QD appears to be a more effective topical treatment than other current options for the inflammatory lesions of rosacea, with at least an equivalent safety and tolerability profile, and could provide physicians and dermatologists with an alternative first-line treatment option.Keywords
Funding Information
- Galderma
This publication has 32 references indexed in Scilit:
- Interventions for rosacea2011
- Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert GroupJournal of the European Academy of Dermatology and Venereology, 2011
- The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalitiesBritish Journal of Dermatology, 2010
- A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trialClinical and Experimental Dermatology, 2010
- RosaceaNew England Journal of Medicine, 2005
- Randomized Placebo-controlled Trial of Metronidazole 1% Cream with Sunscreen SPF 15 in Treatment of RosaceaJournal of Cutaneous Medicine and Surgery, 2002
- Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosaceaJournal of the American Academy of Dermatology, 2001
- Double-blind Comparison of Azelaic Acid 20% Cream and its Vehicle in Treatment of Papulo-pustular RosaceaActa Dermato-Venereologica, 1999
- TREATMENT OF ROSACEA BY METRONIDAZOLEThe Lancet, 1976
- COMPARATIVE EFFECTIVENESS OF TETRACYCLINE AND AMPICILLIN IN ROSACEAThe Lancet, 1971